About Denali Therapeutics
Denali Therapeutics (NASDAQ:DNLI) is a biotechnology firm focused on discovering and developing therapies for patients with neurodegenerative diseases, such as Parkinson's, Alzheimer's, and ALS. Their innovative approach includes leveraging their proprietary drug delivery platform to cross the blood-brain barrier, aiming to bring targeted treatments directly to the brain. Projects in their pipeline range from early discovery to clinical trials, emphasizing collaboration with global pharmaceutical leaders to accelerate development. Objectives center on achieving breakthroughs in molecular understanding and treatment of neurological diseases, ultimately improving patients' lives. Denali Therapeutics is dedicated to pushing the boundaries of neuroscience and transforming the therapeutic landscape for neurodegenerative disorders.
Snapshot
Operations
Products and/or services of Denali Therapeutics
- DNL310 (ETV:IDS) for Hunter syndrome, a brain-penetrant enzyme replacement therapy.
- Biomarker Initiative, designed to identify biomarkers for neurodegenerative diseases.
- RIPK1 inhibitors for treating Alzheimer's disease and ALS.
- ATV (Antibody Transport Vehicle) technology, enhancing drug delivery to the brain.
- DNL151 (LRRK2 inhibitor) aimed at treating Parkinson's disease.
- DNL758 / DNL788, targeting RIPK1 for autoimmune and inflammatory diseases.
Denali Therapeutics executive team
- Dr. Ryan J. Watts Ph.D.Co-Founder, President, CEO & Director
- Dr. Alexander O. Schuth M.D., Ph.D.Co-Founder, CFO, COO & Secretary
- Dr. Dana AndersenChief Technical and Manufacturing Officer
- Mr. Joe Lewcock Ph.D.Chief Scientific Officer
- Mr. Chris Walsh J.D.General Counsel
- Ms. Cindy DunkleChief People Officer
- Ms. Katie PengChief Commercial Officer
- Mr. Peter Chin M.D.Acting Chief Medical Officer & Head of Development